In a recent representation to the U.S. Patent and Trademark Office (USPTO), technology companies, drugmakers, and various industry organizations expressed divided opinions on the utilization of artificial intelligence (AI) in assessing the novelty of inventions in light of prior art. The debate highlights the industry’s struggle to adapt to AI’s growing influence in the patenting process. While some argue that AI can provide more accurate and comprehensive analyses, others believe that it could pose risks or undermine the established procedures for determining patentability. These differing views underscore the complexities and uncertainties that AI introduces to the realm of intellectual property. Further details on this issue can be found in the original article on
Law360.